dorsaVi launches US-based patient registry for low back pain to support reimbursement plans 
CLICK HERE TO CONTACT dorsaVi

Key points:

  • The registry will recruit over 1,500 US-based low back pain patients in the first 18 months.
  • The registry steering committee is headed by Washington DC-based Physical Medicine and Rehabilitation Physician, Dr Mehul Desai.
  • This longitudinal study will utilise dorsaVi’s ViMove medical grade sensors to monitor patients’ responses to various treatments including medications, injection therapies and surgery.
  • It is anticipated that the registry will generate a series of medical publications highlighting the importance of ViMove data in the assessment, diagnosis and treatment of low back pain patients.
  • This registry forms part of dorsaVi’s reimbursement strategy for the US market.

Melbourne, Australia – 27 October 2016: dorsaVi Ltd (ASX: DVL) is pleased to report the first patient has been recruited into its US-based Back Pain and Movement Registry. The registry will recruit 1,500 low back pain patients in the first 18 months with the objective of establishing a better understanding of the relationship between body movement, muscle activity, physical function and a range of other factors which are associated with low back pain.

In the United States alone, total costs related to low back pain exceed US$100 billion per annum1Insurers and other payers are looking for effective treatments which can reduce this significant economic burden and improve patient wellbeing. The registry is an important component in dorsaVi’s reimbursement strategy in the US market.

The registry steering committee is headed by Washington DC-based Physical Medicine and Rehabilitation Physician (PM&R), Dr Mehul Desai. Dr Desai’s practice, International Spine, Pain and Performance Center, and Synergy Manual Physical Therapy LLC, are the first two registry sites. Other sites across the US are currently being recruited. Ethics approval has been provided by The George Washington University Institutional Review Board (IRB).

“The registry findings will provide an increased understanding of low back pain, creating an opportunity to deliver more targeted and earlier interventions that are more likely to be successful. In the changing US healthcare environment, there is a unique opportunity to demonstrate value using dorsaVi technology from a health economic perspective,” said Dr Desai.

“dorsaVi is delighted that a PM&R Physician of Dr Desai’s calibre is leading the registry and we look forward to the addition of other high profile sites in the future” said Dr Andrew Ronchi, CEO dorsaVi.

- END -

Key points:

  • The registry will recruit over 1,500 US-based low back pain patients in the first 18 months.
  • The registry steering committee is headed by Washington DC-based Physical Medicine and Rehabilitation Physician, Dr Mehul Desai.
  • This longitudinal study will utilise dorsaVi’s ViMove medical grade sensors to monitor patients’ responses to various treatments including medications, injection therapies and surgery.
  • It is anticipated that the registry will generate a series of medical publications highlighting the importance of ViMove data in the assessment, diagnosis and treatment of low back pain patients.
  • This registry forms part of dorsaVi’s reimbursement strategy for the US market.

Melbourne, Australia – 27 October 2016: dorsaVi Ltd (ASX: DVL) is pleased to report the first patient has been recruited into its US-based Back Pain and Movement Registry. The registry will recruit 1,500 low back pain patients in the first 18 months with the objective of establishing a better understanding of the relationship between body movement, muscle activity, physical function and a range of other factors which are associated with low back pain.

In the United States alone, total costs related to low back pain exceed US$100 billion per annum1. Insurers and other payers are looking for effective treatments which can reduce this significant economic burden and improve patient wellbeing. The registry is an important component in dorsaVi’s reimbursement strategy in the US market.

The registry steering committee is headed by Washington DC-based Physical Medicine and Rehabilitation Physician (PM&R), Dr Mehul Desai. Dr Desai’s practice, International Spine, Pain and Performance Center, and Synergy Manual Physical Therapy LLC, are the first two registry sites. Other sites across the US are currently being recruited. Ethics approval has been provided by The George Washington University Institutional Review Board (IRB).

“The registry findings will provide an increased understanding of low back pain, creating an opportunity to deliver more targeted and earlier interventions that are more likely to be successful. In the changing US healthcare environment, there is a unique opportunity to demonstrate value using dorsaVi technology from a health economic perspective,” said Dr Desai.

“dorsaVi is delighted that a PM&R Physician of Dr Desai’s calibre is leading the registry and we look forward to the addition of other high profile sites in the future” said Dr Andrew Ronchi, CEO dorsaVi.

- END -

Request more information about dorsaVi

CONTACT ME FOR MORE INFORMATION

Randomised Controlled Trial with dorsaVi technology finds back pain patients monitored and treated using dorsaVi's sensors had significant, sustained improvements in pain and function.

Recent news: What's happening at dorsaVi 

ViPerform and the NFL: How Loren Landow uses objective data to assess risk of injury

1Estimating Cost of Care for Patients With Acute Low Back Pain: A Retrospective Review of Patient Records, William Thomas Crow, DO; David R. Willis, DO, MBA. The Journal of the American Osteopathic Association, April 2009, Vol. 109, 229-233.

1Estimating Cost of Care for Patients With Acute Low Back Pain: A Retrospective Review of Patient Records, William Thomas Crow, DO; David R. Willis, DO, MBA. The Journal of the American Osteopathic Association, April 2009, Vol. 109, 229-233.

Fix the following errors:
Hide